FCRL3, EFEMP1, ANKRD29, and STOX2 may serve as potential biomarkers for monitoring the transition from precancerous lesions to gastric cancer, offering insights into the mechanisms of gastric carcinogenesis and supporting early diagnosis and intervention strategies. This evidence concerns the gene STOX2 and gastric cancer.